Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics

Nov 06, 2024 - financialpost.com
Sonrai Analytics, an AI precision medicine company, is set to bring its cloud-based AI technology, Sonrai Discovery, to the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital. The technology will help the center manage and analyze its vast and complex data for more meaningful insights and faster analysis, accelerating oncological research into personalized therapies. The platform will act as the first point of access to the center's data, allowing researchers, bioinformaticians, and clinicians to collaborate within one centralized environment.

Sonrai Discovery will also ensure data security and compliance with data protection regulations to safeguard patient information. The platform will enable the Termeer Center to maximize its research output in high-impact publications and enhance grant funding opportunities for oncological research. It will also bridge the gap between its bioinformaticians and translational researchers, creating time efficiencies and collaborative efforts, while simultaneously creating a pathway for skill enrichment for postdocs and fellows.

Key takeaways:

  • Sonrai Analytics is working with the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital to provide advanced analytics for therapeutic development.
  • The Termeer Center will use Sonrai's AI technology platform, Sonrai Discovery, to integrate and analyze diverse data types, including multi-omics and clinical data.
  • Sonrai Discovery will accelerate the process from raw data to analysis, enhance data security, and ensure compliance with data protection regulations.
  • Prof. Darragh McArt, CEO and Founder of Sonrai Analytics, expressed commitment to supporting innovation in precision medicine and developing novel therapeutics to help patients beat cancer.
View Full Article

Comments (0)

Be the first to comment!